Viking Therapeutics (VKTX) Competitors $28.16 +0.44 (+1.59%) Closing price 07/3/2025 03:57 PM EasternExtended Trading$28.04 -0.12 (-0.43%) As of 07/3/2025 04:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock VKTX vs. MDGL, LLY, QGEN, MRNA, VTRS, ASND, BPMC, BBIO, VRNA, and ROIVShould you be buying Viking Therapeutics stock or one of its competitors? The main competitors of Viking Therapeutics include Madrigal Pharmaceuticals (MDGL), Eli Lilly and Company (LLY), Qiagen (QGEN), Moderna (MRNA), Viatris (VTRS), Ascendis Pharma A/S (ASND), Blueprint Medicines (BPMC), BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), and Roivant Sciences (ROIV). These companies are all part of the "medical" sector. Viking Therapeutics vs. Its Competitors Madrigal Pharmaceuticals Eli Lilly and Company Qiagen Moderna Viatris Ascendis Pharma A/S Blueprint Medicines BridgeBio Pharma Verona Pharma PLC American Depositary Share Roivant Sciences Viking Therapeutics (NASDAQ:VKTX) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, media sentiment, dividends, earnings and risk. Do analysts rate VKTX or MDGL? Viking Therapeutics presently has a consensus price target of $87.15, suggesting a potential upside of 209.50%. Madrigal Pharmaceuticals has a consensus price target of $420.63, suggesting a potential upside of 40.92%. Given Viking Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Viking Therapeutics is more favorable than Madrigal Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Viking Therapeutics 0 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 3.00Madrigal Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.89 Which has stronger earnings and valuation, VKTX or MDGL? Viking Therapeutics has higher earnings, but lower revenue than Madrigal Pharmaceuticals. Viking Therapeutics is trading at a lower price-to-earnings ratio than Madrigal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioViking TherapeuticsN/AN/A-$109.96M-$1.15-24.49Madrigal Pharmaceuticals$180.13M36.79-$465.89M-$18.05-16.54 Is VKTX or MDGL more profitable? Viking Therapeutics has a net margin of 0.00% compared to Madrigal Pharmaceuticals' net margin of -123.38%. Viking Therapeutics' return on equity of -14.41% beat Madrigal Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Viking TherapeuticsN/A -14.41% -14.02% Madrigal Pharmaceuticals -123.38%-50.54%-37.19% Which has more risk and volatility, VKTX or MDGL? Viking Therapeutics has a beta of 0.62, indicating that its share price is 38% less volatile than the S&P 500. Comparatively, Madrigal Pharmaceuticals has a beta of -1.05, indicating that its share price is 205% less volatile than the S&P 500. Does the media favor VKTX or MDGL? In the previous week, Viking Therapeutics had 10 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 14 mentions for Viking Therapeutics and 4 mentions for Madrigal Pharmaceuticals. Madrigal Pharmaceuticals' average media sentiment score of 0.98 beat Viking Therapeutics' score of 0.35 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viking Therapeutics 6 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Madrigal Pharmaceuticals 2 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders hold more shares of VKTX or MDGL? 76.0% of Viking Therapeutics shares are owned by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. 4.1% of Viking Therapeutics shares are owned by insiders. Comparatively, 21.5% of Madrigal Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. SummaryViking Therapeutics beats Madrigal Pharmaceuticals on 11 of the 16 factors compared between the two stocks. Get Viking Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VKTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VKTX vs. The Competition Export to ExcelMetricViking TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.16B$2.88B$5.50B$9.01BDividend YieldN/A2.43%5.38%4.10%P/E Ratio-24.4921.5627.6020.30Price / SalesN/A172.76368.97103.88Price / CashN/A41.9536.6357.47Price / Book3.567.518.055.68Net Income-$109.96M-$55.05M$3.18B$249.13M7 Day Performance6.18%4.61%2.82%3.30%1 Month Performance4.30%4.89%3.70%5.20%1 Year Performance-44.20%5.84%35.41%21.38% Viking Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VKTXViking Therapeutics4.3689 of 5 stars$28.16+1.6%$87.15+209.5%-44.2%$3.16BN/A-24.4920Trending NewsInsider TradeMDGLMadrigal Pharmaceuticals4.1045 of 5 stars$305.20+1.5%$420.63+37.8%+9.9%$6.78B$317.38M-16.9190LLYEli Lilly and Company4.9865 of 5 stars$777.88+0.3%$1,011.61+30.0%-13.2%$737.23B$45.04B63.2947,000Trending NewsQGENQiagen4.0602 of 5 stars$48.08+0.6%$49.40+2.7%+22.5%$10.69B$1.98B120.555,765Dividend AnnouncementMRNAModerna4.3867 of 5 stars$27.54+1.4%$46.61+69.2%-73.7%$10.65B$3.24B-3.155,800Options VolumeVTRSViatris3.3111 of 5 stars$8.95-0.7%$10.40+16.2%-10.9%$10.50B$14.74B-2.8232,000ASNDAscendis Pharma A/S3.6796 of 5 stars$171.21-0.6%$220.67+28.9%+29.7%$10.47B$393.54M-27.261,017Analyst ForecastBPMCBlueprint Medicines1.7442 of 5 stars$128.15+0.0%$128.06-0.1%+17.6%$8.28B$562.12M-51.88640BBIOBridgeBio Pharma4.7061 of 5 stars$43.14-3.8%$58.85+36.4%+74.8%$8.19B$221.90M-12.22400Insider TradeAnalyst RevisionVRNAVerona Pharma PLC American Depositary Share2.6682 of 5 stars$94.51+0.7%$101.10+7.0%+480.4%$8.05B$42.28M-47.2630Positive NewsAnalyst ForecastROIVRoivant Sciences1.5719 of 5 stars$11.28-1.0%$17.50+55.1%+3.5%$7.67B$29.05M-45.12860 Related Companies and Tools Related Companies Madrigal Pharmaceuticals Competitors Eli Lilly and Company Competitors Qiagen Competitors Moderna Competitors Viatris Competitors Ascendis Pharma A/S Competitors Blueprint Medicines Competitors BridgeBio Pharma Competitors Verona Pharma PLC American Depositary Share Competitors Roivant Sciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VKTX) was last updated on 7/4/2025 by MarketBeat.com Staff From Our Partners379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredElon’s RevengeElon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is th...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTop Picks for Trump’s Pro-Crypto AmericaMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredGold: Now legal tender in many statesThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viking Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viking Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VKTX Stock Alerts